Compare Aurobindo Pharma with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WYETH - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WYETH AUROBINDO PHARMA/
WYETH
 
P/E (TTM) x 18.0 27.7 64.9% View Chart
P/BV x 3.9 5.3 72.7% View Chart
Dividend Yield % 0.3 1.3 21.2%  

Financials

 AUROBINDO PHARMA   WYETH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
WYETH
Mar-13
AUROBINDO PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs8301,044 79.5%   
Low Rs527818 64.4%   
Sales per share (Unadj.) Rs333.9298.6 111.8%  
Earnings per share (Unadj.) Rs40.457.2 70.5%  
Cash flow per share (Unadj.) Rs51.858.4 88.6%  
Dividends per share (Unadj.) Rs2.5017.00 14.7%  
Dividend yield (eoy) %0.41.8 20.2%  
Book value per share (Unadj.) Rs237.1249.5 95.0%  
Shares outstanding (eoy) m585.9122.72 2,578.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.03.1 65.2%   
Avg P/E ratio x16.816.3 103.4%  
P/CF ratio (eoy) x13.115.9 82.2%  
Price / Book Value ratio x2.93.7 76.7%  
Dividend payout %6.229.7 20.9%   
Avg Mkt Cap Rs m397,56921,157 1,879.2%   
No. of employees `00017.90.5 3,629.1%   
Total wages/salary Rs m25,849400 6,462.2%   
Avg. sales/employee Rs Th10,956.913,787.4 79.5%   
Avg. wages/employee Rs Th1,447.7813.0 178.1%   
Avg. net profit/employee Rs Th1,324.32,643.3 50.1%   
INCOME DATA
Net Sales Rs m195,6366,783 2,884.0%  
Other income Rs m1,553353 440.5%   
Total revenues Rs m197,1897,136 2,763.3%   
Gross profit Rs m39,5191,617 2,443.5%  
Depreciation Rs m6,68027 25,110.9%   
Interest Rs m2,6266 47,745.5%   
Profit before tax Rs m31,7671,938 1,639.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-5 17,266.7%   
Tax Rs m7,269632 1,149.7%   
Profit after tax Rs m23,6451,301 1,818.1%  
Gross profit margin %20.223.8 84.7%  
Effective tax rate %22.932.6 70.1%   
Net profit margin %12.119.2 63.0%  
BALANCE SHEET DATA
Current assets Rs m153,6456,984 2,200.0%   
Current liabilities Rs m120,4292,056 5,857.7%   
Net working cap to sales %17.072.6 23.4%  
Current ratio x1.33.4 37.6%  
Inventory Days Days13599 136.2%  
Debtors Days Days6424 266.1%  
Net fixed assets Rs m103,909244 42,533.2%   
Share capital Rs m586227 257.9%   
"Free" reserves Rs m138,3225,441 2,542.3%   
Net worth Rs m138,9085,668 2,450.7%   
Long term debt Rs m1,80025 7,198.0%   
Total assets Rs m264,5447,901 3,348.2%  
Interest coverage x13.1353.3 3.7%   
Debt to equity ratio x00 293.7%  
Sales to assets ratio x0.70.9 86.1%   
Return on assets %9.916.5 60.1%  
Return on equity %17.022.9 74.2%  
Return on capital %23.834.0 70.0%  
Exports to sales %49.60.2 22,746.7%   
Imports to sales %18.836.3 51.7%   
Exports (fob) Rs m97,09115 656,021.6%   
Imports (cif) Rs m36,7412,465 1,490.3%   
Fx inflow Rs m97,31615 640,239.5%   
Fx outflow Rs m40,5892,677 1,516.1%   
Net fx Rs m56,727-2,662 -2,131.0%   
CASH FLOW
From Operations Rs m16,220923 1,757.0%  
From Investments Rs m-28,768317 -9,078.0%  
From Financial Activity Rs m19,191-481 -3,989.7%  
Net Cashflow Rs m6,656759 876.9%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 7.2 384.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 30.4 33.6%  
Shareholders   69,601 21,978 316.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS